CureVac (CVAC) AI Stock Analysis

• Market Cap: $1.18B
• Dividend Yield: N/A
• Average Volume (3M): 488.11K
• Price to Earnings (P/E): 5.7
• Beta (1Y): 1.15
• Revenue Growth: 799.36%
• EPS Growth: N/A
• Country: US
• Employees: 825
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 225,181,640
• 10 Day Avg. Volume: 612,574
• 30 Day Avg. Volume: 488,114
• PEG Ratio: -0.03
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 1.38
• P/FCF Ratio: 8.86
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $6.00 ▲(11.94% Upside)

CureVac's strong financial performance and attractive valuation are the primary drivers of its overall score. The company's robust profitability metrics and low leverage enhance its financial stability. However, technical analysis indicates some short-term bearish momentum, which slightly offsets the positive financial and valuation aspects.

Positive Factors

Strategic Merger

The merger with BioNTech is a strategic move that could enhance CureVac's market positioning and operational capabilities, leveraging complementary technologies in mRNA science.

Patent Litigation Resolution

Resolving patent litigation provides financial gain and operational clarity, allowing CureVac to focus on core business activities and strengthening its industry position.

Cash Flow Improvement

Improved cash flow generation indicates strong operational efficiency, enhancing financial flexibility and supporting long-term strategic investments.

Negative Factors

Revenue Decline

A decline in revenue growth suggests potential challenges in market demand or competitive pressures, which could impact future profitability and market share.

Financial Losses

Reporting financial losses highlights operational difficulties and could strain resources, affecting the company's ability to invest in R&D and growth initiatives.

Decreased Cash Reserves

A reduction in cash reserves may limit CureVac's financial flexibility, potentially impacting its ability to fund ongoing projects and respond to market opportunities.

CureVac Business Overview & Revenue Model

Company Description

CureVac (CVAC) is a biopharmaceutical company that specializes in the development of mRNA-based therapies and vaccines. Founded in Germany, the company aims to harness the power of messenger RNA to treat various diseases, including infectious diseases, cancer, and rare diseases. CureVac is at the forefront of the mRNA technology sector, focusing on creating innovative solutions that can potentially transform the landscape of medicine and immunotherapy.

How the Company Makes Money

CureVac generates revenue primarily through the development and commercialization of its mRNA-based products. Key revenue streams include partnerships and collaborations with pharmaceutical companies, government contracts for vaccine development, and potential future sales of its therapeutic products once they receive regulatory approval. Significant partnerships, such as those with global pharmaceutical companies and public health organizations, contribute to funding and resource sharing, enhancing its research and development capabilities. Additionally, CureVac may receive milestone payments and royalties from its collaborators, further bolstering its earnings as it advances its pipeline of mRNA therapeutics and vaccines.

CureVac Financial Statement Overview

Summary

CureVac demonstrates a strong financial position with impressive profitability metrics and a solid balance sheet. The company has effectively managed its debt levels and equity, resulting in high returns on equity. While revenue growth has faced challenges, the company has shown resilience in improving its cash flow generation.

Income Statement

CureVac's income statement shows a strong recovery with a TTM gross profit margin of 87.6% and a net profit margin of 34.5%. The EBIT and EBITDA margins are also robust at 39.9% and 43.5%, respectively. However, the revenue growth rate has declined by 2.5% in the TTM period, indicating potential challenges in sustaining revenue growth.

Balance Sheet

The balance sheet is solid with a low debt-to-equity ratio of 0.058, indicating low leverage. The return on equity is strong at 29.6%, reflecting efficient use of equity to generate profits. The equity ratio stands at 85.1%, showcasing a strong equity base relative to total assets.

Cash Flow

CureVac's cash flow statement highlights a significant improvement in free cash flow growth at 36.7% in the TTM period. The operating cash flow to net income ratio is healthy at 2.56, suggesting strong cash generation relative to net income. However, the free cash flow to net income ratio of 0.91 indicates that not all net income is translating into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	510.51M	535.18M	53.76M	67.42M	102.99M	48.90M
Gross Profit	484.00M	429.35M	-70.61M	-116.57M	-135.21M	34.73M
EBITDA	238.59M	209.69M	-234.09M	-209.39M	-386.49M	-123.09M
Net Income	193.64M	162.19M	-260.17M	-249.03M	-411.72M	-129.07M
Balance Sheet
Total Assets	688.88M	802.83M	788.25M	860.47M	1.16B	1.51B
Cash, Cash Equivalents and Short-Term Investments	395.81M	485.37M	405.11M	500.28M	816.11M	1.33B
Total Debt	36.03M	38.97M	41.82M	42.09M	28.89M	30.09M
Total Liabilities	102.51M	106.22M	271.31M	327.22M	469.77M	800.01M
Stockholders Equity	586.37M	696.61M	516.94M	533.25M	688.48M	711.35M
Cash Flow
Free Cash Flow	196.15M	83.41M	-323.09M	-379.40M	-861.03M	475.05M
Operating Cash Flow	204.08M	101.85M	-267.89M	-286.18M	-733.13M	522.40M
Investing Cash Flow	-7.93M	-18.44M	-55.20M	-93.50M	-127.90M	-45.27M
Financing Cash Flow	-5.39M	-5.11M	230.89M	63.17M	344.96M	819.83M

CureVac Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVAC, the sentiment is Neutral. The current price of 5.36 is above the 20-day moving average (MA) of 5.35, below the 50-day MA of 5.36, and above the 200-day MA of 4.47, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 25.32 is Positive, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVAC.

CureVac Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	70 Outperform	$1.18B	5.74	―	―	799.36%	―
STOK	59 Neutral	$1.28B	34.64	15.02%	―	1128.17%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	48 Neutral	$1.28B	―	-129.32%	―	597.19%	0.45%
LENZ	46 Neutral	$718.42M	―	-28.78%	―	―	70.19%
ABCL	41 Neutral	$1.35B	―	-16.81%	―	7.16%	3.95%
ELVN	36 Underperform	$1.13B	-9.50	-25.26%	―	―	-3.53%

CureVac Corporate Events

CureVac Announces Extraordinary Meeting for Merger with BioNTech

On October 24, 2025, CureVac N.V. announced an extraordinary general meeting of shareholders scheduled for November 25, 2025, to discuss a merger proposal with BioNTech SE. The agenda includes a legal merger where CureVac will merge into CureVac Merger B.V., with BioNTech acquiring ordinary shares in exchange for American Depositary Shares. This merger is part of a strategic reorganization aimed at enhancing CureVac’s market positioning and operational capabilities.

CureVac Reports Financial Losses in Mid-2025

CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline in revenue compared to the previous year. The company reported a net loss for the period, highlighting challenges in its financial performance. The financial results indicate a decrease in cash and cash equivalents, reflecting operational difficulties and potential impacts on stakeholders and market positioning.

CureVac Resolves Patent Litigation with Pfizer/BioNTech

On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive $740 million and royalties on U.S. vaccine sales. Additionally, CureVac will grant a non-exclusive license to BioNTech and Pfizer for mRNA-based products, which will expand globally upon BioNTech’s acquisition of CureVac. This resolution is expected to streamline CureVac’s operations and strengthen its industry position.